HIV patients test weekly shots to replace daily pills

NCT ID NCT05271370

Terminated Disease control Sponsor: CytoDyn, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether HIV patients who already had the virus under control could switch to weekly injections of leronlimab (PRO 140) instead of their usual daily pills. The goal was to see if the drug alone could keep the virus suppressed safely over a longer period. The trial was terminated early, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: leronlimab (PRO 140)
What this could lead to: If successful, this could show that leronlimab alone can keep HIV under control long-term, potentially reducing the need for daily oral medications.
What could go wrong: The study was terminated early with only 56 participants, so results are limited. It is unclear if leronlimab monotherapy can reliably prevent viral rebound, and there may be side effects like injection reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV-1-INFECTION

Contacts and locations

Locations

Quest Clinical Research

San Francisco, California, 94115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.